Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

Summary

This is a Phase 1b, combined multiple dose subcutaneous (SC) bioavailability (BA) and multiple ascending dose (MAD) study evaluating safety, tolerability and BA of SC XmAb7195 in healthy subjects and in subjects with atopic disease.

Timeline

Start

2016-08-17

Primary completion

2017-02-24

Completion

2017-02-24

Drugs

Indications